Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 50 articles:
HTML format
Text format



Single Articles


    November 2016
  1. HEGEDUS L, Garay T, Molnar E, Varga K, et al
    The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.
    Int J Cancer. 2016 Nov 4. doi: 10.1002/ijc.30503.
    PubMed     Text format     Abstract available


  2. DESCH A, Gebhardt C, Utikal J, Schneider SW, et al
    D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
    Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30498.
    PubMed     Text format     Abstract available


    September 2016
  3. SARRABAYROUSE G, Pich C, Teiti I, Tilkin-Mariame AF, et al
    Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30422.
    PubMed     Text format     Abstract available


    August 2016
  4. ZHANG W, Liu H, Yin J, Wu W, et al
    Genetic Variants in the PIWI-piRNA Pathway Gene DCP1A Predict Melanoma Disease-specific Survival.
    Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30409.
    PubMed     Text format     Abstract available


  5. ROCKBERG J, Amelio JM, Taylor A, Jorgensen L, et al
    Epidemiology of cutaneous melanoma in Sweden - stage specific survival and rate of recurrence.
    Int J Cancer. 2016 Aug 26. doi: 10.1002/ijc.30407.
    PubMed     Text format     Abstract available


    June 2016
  6. VAYSSE A, Fang S, Brossard M, Wei Q, et al
    A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants.
    Int J Cancer. 2016 Jun 27. doi: 10.1002/ijc.30245.
    PubMed     Text format     Abstract available


  7. MAXWELL R, Garzon-Muvdi T, Lipson EJ, Sharfman WH, et al
    BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
    Int J Cancer. 2016 Jun 25. doi: 10.1002/ijc.30241.
    PubMed     Text format     Abstract available


  8. MIRZAEI H, Naseri G, Rezaee R, Mohammadi M, et al
    Curcumin: A new candidate for melanoma therapy?
    Int J Cancer. 2016 Jun 9. doi: 10.1002/ijc.30224.
    PubMed     Text format     Abstract available


  9. GANDINI S, Ferrucci PF, Botteri E, Tosti G, et al
    Prognostic significance of hematological profiles in melanoma patients.
    Int J Cancer. 2016 Jun 2. doi: 10.1002/ijc.30215.
    PubMed     Text format     Abstract available


    May 2016
  10. ORTEGA-MARTINEZ I, Gardeazabal J, Erramuzpe A, Sanchez-Diez A, et al
    Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early stage melanoma.
    Int J Cancer. 2016 May 23. doi: 10.1002/ijc.30202.
    PubMed     Text format     Abstract available


  11. POTRONY M, Carreras E, Aranda F, Zimmer L, et al
    Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.
    Int J Cancer. 2016 May 11. doi: 10.1002/ijc.30184.
    PubMed     Text format     Abstract available


    April 2016
  12. TAYLOR NJ, Thomas NE, Anton-Culver H, Armstrong BK, et al
    Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.
    Int J Cancer. 2016 Apr 22. doi: 10.1002/ijc.30157.
    PubMed     Text format     Abstract available


  13. SMALLEY KS, Fedorenko IV, Kenchappa R, Sahebjam S, et al
    Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30147.
    PubMed     Text format     Abstract available


  14. ANDZINSKI L, Kasnitz N, Stahnke S, Wu CF, et al
    Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.
    Int J Cancer. 2016;138:1982-93.
    PubMed     Text format     Abstract available


    March 2016
  15. SIMBERG-DANELL C, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, et al
    Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
    Int J Cancer. 2016 Mar 23. doi: 10.1002/ijc.30103.
    PubMed     Text format     Abstract available


  16. ROWE CJ, Tang F, Hughes MC, Rodero MP, et al
    Molecular markers to complement sentinel node status in predicting survival in patients with high risk locally invasive melanoma.
    Int J Cancer. 2016 Mar 14. doi: 10.1002/ijc.30085.
    PubMed     Text format     Abstract available


    February 2016
  17. NAGORE E, Heidenreich B, Rachakonda S, Garcia-Casado Z, et al
    TERT promoter mutations in melanoma survival.
    Int J Cancer. 2016 Feb 13. doi: 10.1002/ijc.30042.
    PubMed     Text format     Abstract available


  18. DEVARAPU SK, Mamidi S, Ploger F, Dill O, et al
    Cytotoxic Activity Against Human Neuroblastoma and Melanoma Cells Mediated by IgM Antibodies Derived from Peripheral Blood of Healthy Donors.
    Int J Cancer. 2016 Feb 2. doi: 10.1002/ijc.30025.
    PubMed     Text format     Abstract available


    January 2016
  19. ERIKSSON H, Lyth J, Andersson TM
    The proportion cured of patients diagnosed with stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study.
    Int J Cancer. 2016 Jan 27. doi: 10.1002/ijc.30023.
    PubMed     Text format     Abstract available


    December 2015
  20. OROUJI E, Orouji A, Gaiser T, Larribere L, et al
    MAP Kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Int J Cancer. 2015 Dec 18. doi: 10.1002/ijc.29970.
    PubMed     Text format     Abstract available


  21. THOMSEN FB, Folkvaljon Y, Garmo H, Robinson D, et al
    Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.
    Int J Cancer. 2015 Dec 14. doi: 10.1002/ijc.29961.
    PubMed     Text format     Abstract available


    September 2015
  22. LERRO CC, Koutros S, Andreotti G, Hines CJ, et al
    Use of acetochlor and cancer incidence in the Agricultural Health Study.
    Int J Cancer. 2015;137:1167-75.
    PubMed     Text format     Abstract available


    August 2015
  23. WISTUBA-HAMPRECHT K, Di Benedetto S, Schilling B, Sucker A, et al
    Phenotypic characterization and prognostic impact of circulating gammadelta and alphabeta T-cells in metastatic malignant melanoma.
    Int J Cancer. 2015 Aug 27. doi: 10.1002/ijc.29818.
    PubMed     Text format     Abstract available


  24. CORREA D, Somoza RA, Lin P, Schiemann WP, et al
    Mesenchymal Stem Cells regulate Melanoma Cancer Cells extravasation to bone and liver at their perivascular niche.
    Int J Cancer. 2015 Aug 1. doi: 10.1002/ijc.29709.
    PubMed     Text format     Abstract available


  25. AL-AHMADY ZS, Scudamore CL, Kostarelos K
    Triggered doxorubicin release in solid tumors from thermosensitive liposome-peptide hybrids: Critical parameters and therapeutic efficacy.
    Int J Cancer. 2015;137:731-43.
    PubMed     Text format     Abstract available


    June 2015
  26. RIBERO S, Davies JR, Glass D, Quaglino P, et al
    RE:RE: High naevus counts confer a favorable prognosis in melanoma patients.
    Int J Cancer. 2015 Jun 24. doi: 10.1002/ijc.29652.
    PubMed     Text format    


  27. AUTIER P, Funck-Brentano E, Aegerter P, Boniol M, et al
    Re: High nevus counts confer a favorable prognosis in melanoma patients by S Ribero and co-workers, published in the International Journal of Cancer, 2015 (Online 21 March 2015).
    Int J Cancer. 2015 Jun 20. doi: 10.1002/ijc.29648.
    PubMed     Text format    


    May 2015
  28. WAGNER NB, Weide B, Reith M, Tarnanidis K, et al
    Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.
    Int J Cancer. 2015 May 27. doi: 10.1002/ijc.29619.
    PubMed     Text format     Abstract available


  29. WALLINGFORD SC, Iannacone MR, Youlden DR, Baade PD, et al
    Comparison of melanoma incidence and trends among youth under 25 years in Australia and England, 1990-2010.
    Int J Cancer. 2015 May 8. doi: 10.1002/ijc.29598.
    PubMed     Text format     Abstract available


  30. HELGADOTTIR H, Hoiom V, Tuominen R, Jonsson G, et al
    CDKN2A mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Int J Cancer. 2015 May 5. doi: 10.1002/ijc.29595.
    PubMed     Text format     Abstract available


    April 2015
  31. BROSSARD M, Fang S, Vaysse A, Wei Q, et al
    Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk.
    Int J Cancer. 2015 Apr 17. doi: 10.1002/ijc.29570.
    PubMed     Text format     Abstract available


    March 2015
  32. BRAMANTE S, Kaufmann JK, Veckman V, Liikanen I, et al
    Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Int J Cancer. 2015 Mar 26. doi: 10.1002/ijc.29536.
    PubMed     Text format     Abstract available


  33. RIBERO S, Davies JR, Requena C, Carrera C, et al
    High naevus counts confer a favourable prognosis in melanoma patients.
    Int J Cancer. 2015 Mar 21. doi: 10.1002/ijc.29525.
    PubMed     Text format     Abstract available


  34. WANG J, Yu F, Jia X, Iwanowycz S, et al
    MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth.
    Int J Cancer. 2015;136:E602-13.
    PubMed     Text format     Abstract available


  35. MAULDIN IS, Wang E, Deacon DH, Olson WC, et al
    TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.
    Int J Cancer. 2015 Mar 12. doi: 10.1002/ijc.29515.
    PubMed     Text format     Abstract available


  36. JOSHI S, Wels C, Beham-Schmid C, Fukunaga-Kalabis M, et al
    Galpha(13) mediates human cytomegalovirus-encoded chemokine receptor US28 induced cell death in melanoma.
    Int J Cancer. 2015 Mar 6. doi: 10.1002/ijc.29506.
    PubMed     Text format     Abstract available


  37. DOBERSTEIN K, Harter PN, Haberkorn U, Bretz NP, et al
    Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.
    Int J Cancer. 2015;136:E326-39.
    PubMed     Text format     Abstract available


    February 2015
  38. LAUBER S, Wong S, Cutz JC, Tanaka M, et al
    Novel function of Oncostatin M as a potent tumour-promoting agent in lung.
    Int J Cancer. 2015;136:831-43.
    PubMed     Text format     Abstract available


  39. SIURALA M, Bramante S, Vassilev L, Hirvinen M, et al
    Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
    Int J Cancer. 2015;136:945-54.
    PubMed     Text format     Abstract available


  40. SADEGH L, Chen PW, Brown JR, Han Z, et al
    NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.
    Int J Cancer. 2015 Feb 14. doi: 10.1002/ijc.29480.
    PubMed     Text format     Abstract available


    January 2015
  41. JUNG JW, Overgaard NH, Burke MT, Isbel N, et al
    Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?
    Int J Cancer. 2015 Jan 22. doi: 10.1002/ijc.29450.
    PubMed     Text format     Abstract available


  42. CHENG M, Ahmed M, Xu H, Cheung NK, et al
    Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Int J Cancer. 2015;136:476-86.
    PubMed     Text format     Abstract available


  43. YUAN H, Liu H, Liu Z, Zhu D, et al
    Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival.
    Int J Cancer. 2015 Jan 13. doi: 10.1002/ijc.29429.
    PubMed     Text format     Abstract available


  44. YUE C, Xu J, Tan Estioko MD, Kotredes KP, et al
    Host STAT2/type I interferon axis controls tumor growth.
    Int J Cancer. 2015;136:117-26.
    PubMed     Text format     Abstract available


  45. GEBREMESKEL S, LeVatte T, Liwski RS, Johnston B, et al
    The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer.
    Int J Cancer. 2015;136:234-40.
    PubMed     Text format     Abstract available


    December 2014
  46. JOUVE N, Bachelier R, Despoix N, Blin MG, et al
    CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation.
    Int J Cancer. 2014 Dec 2. doi: 10.1002/ijc.29370.
    PubMed     Text format     Abstract available


    November 2014
  47. KVASKOFF M, Pandeya N, Green AC, Perry S, et al
    Solar elastosis and cutaneous melanoma: A site-specific analysis.
    Int J Cancer. 2014 Nov 18. doi: 10.1002/ijc.29335.
    PubMed     Text format     Abstract available


  48. NEWTON-BISHOP JA, Davies JR, Latheef F, Randerson-Moor J, et al
    25-hydroxyvitamin D /D levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort.
    Int J Cancer. 2014 Nov 18. doi: 10.1002/ijc.29334.
    PubMed     Text format     Abstract available


  49. TUOMINEN R, Jewell R, van den Oord JJ, Wolter P, et al
    MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
    Int J Cancer. 2014 Nov 15. doi: 10.1002/ijc.29332.
    PubMed     Text format     Abstract available


  50. TAYLOR NJ, Reiner AS, Begg CB, Cust AE, et al
    Inherited variation at MC1R and ASIP and association with melanoma-specific survival.
    Int J Cancer. 2014 Nov 10. doi: 10.1002/ijc.29317.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Pfizer Oncology.

Design: